Skip to main content
SpringerLink
Log in

Retigabine in partial seizures: profile report

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Plosker GL, Scott LJ. Retigabine in partial seizures. CNS Drugs 2006; 20(7): 601–8

    Article  PubMed  CAS  Google Scholar 

  2. Perucca E. Retigabine in partial seizures: a viewpoint. CNS Drugs 2006; 20(7): 609

    Article  Google Scholar 

  3. Eadie M. Retigabine in partial seizures: a viewpoint. CNS Drugs 2006; 20(7): 609–10

    Article  Google Scholar 

  4. Walker MC, Sander JW. New anti-epileptic drugs. Expert Opin Investig Drugs 1999 Oct; 8(10): 1497–510

    Article  PubMed  CAS  Google Scholar 

  5. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282: 73–6

    Article  PubMed  CAS  Google Scholar 

  6. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000 Dec; 50(12): 1063–70

    PubMed  CAS  Google Scholar 

  7. Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005 Spring; 11(1): 1–20

    Article  PubMed  CAS  Google Scholar 

  8. Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000 Sep; 58(3): 591–600

    PubMed  CAS  Google Scholar 

  9. Wickenden AD, Zou A, Wagoner PK, et al. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001 Jan; 132(2): 381–4

    Article  PubMed  CAS  Google Scholar 

  10. Porter R, Alves W, Nohria V, et al. Randomized, multicenter, dose-ranging trial of retigabine as adjunctive treatment for partial-onset seizures [abstract no. 0160]. J Neurol Sci 2005; 238 Suppl.: S141

    Google Scholar 

  11. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Costa Mesa (CA): Valeant Pharmaceuticals International, 2006. (Data on file)

  12. Retigabine adjunctive therapy in patients with partial-onset seizures: tolerability of different titration rates in a double-blind trial. Costa Mesa (CA): Valeant Pharmaceuticals International, 2006. (Data on file)

  13. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61: 1–48

    Article  PubMed  Google Scholar 

  14. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15: 405–17

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Retigabine in partial seizures: profile report. Drugs Ther. Perspect 22, 5–6 (2006). https://doi.org/10.2165/00042310-200622120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622120-00002

Search

Navigation